AVXL Stock Summary and Trading Ideas (Anavex Life Sciences Corp. | NASDAQ:AVXL)

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Anavex Life Sciences Corp. trades on the NASDAQ stock market under the symbol AVXL.

As of January 10, 2025, AVXL stock price declined to $11.23 with 1,769,405 million shares trading.

AVXL has a market cap of $952.25 million. This is considered a Small Cap stock.

In the last 3 years, AVXL traded as high as $15.57 and as low as $3.25.

The top ETF exchange traded funds that AVXL belongs to (by Net Assets): VTI, IWM, VXF, XBI, IBB.

AVXL has outperformed the market in the last year with a return of +79.7%, while the SPY ETF gained +23.3%. In the last 3 month period, AVXL beat the market returning +119.8%, while SPY returned +1.1%. However, in the most recent 2 weeks AVXL has underperformed the stock market by returning -7.3%, while SPY returned -2.4%.

AVXL support price is $10.63 and resistance is $12.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVXL shares will trade within this expected range on the day.